The MiniPDX® test can provide drug sensitivity results in as little as 7 days vs. the 4-6 months needed for traditional PDX results. Given the time savings of MiniPDX® vs traditional PDX, it is natural to ask how results correlate between the two model types. In a published study, LIDE used 26 PDX models generated from patient tumor samples, including 14 gastric cancers, 10 lung cancers and 2 pancreatic cancers to demonstrate that drug responses in the PDX tumor graft assays correlated well with those in the corresponding MiniPDX assays. The positive predictive value of MiniPDX was 92% vs. PDX, and the negative predictive value was 81% with a sensitivity of 80% and a specificity of 93%.
Fig. Comparing efficacy results of drug S1 in PDX assays vs. equivalent MiniPDX assays.
PDX is well studied and shown to be 89% correlated with clinical result. Taken together with MiniPDX® results, this means MiniPDX® is 82% correlated with clinical results, by calculation. In China, LIDE has verified this in the clinical setting, with over 2600 treated cases at over 80% effectiveness.
Several papers have been published supporting MiniPDX®:
Download all of our papers here.
Application in Drug R&D
The high correlation between drug responses of paired MiniPDX® and PDX tumor graft assay, as well as translational data, suggest that MiniPDX® assay can be an effective pre-clinical testing tool in drug R&D.
Applications of MiniPDX in Drug R&D:
|Drug Development Phase||MiniPDX Benefit|
|Lead Optimization||Fast screening of candidate molecules to identify which is best for further resource investment|
|Lead Validation||Post in-vitro studies, MiniPDX screens using PDX cells can identify the best PDX model for further in-vivo validation|
|Pre-clinical Development||MiniPDX Mouse Trial using fresh tumor samples can identify or verify potential clinical indications|
|Clinical Development||MiniPDX + OMICS analysis can reveal biomarkers for patient stratification and trial recruitment strategy|
In addition, by combining MiniPDX® functional testing with proprietary LIDE OncoVee™ K-cell technology , drug development companies can also identify biomarkers that will be useful in patient stratification for clinical trials. LIDE calls this combined (MiniPDX® trial + omics analysis) approach “Functional Diagnosis” and we believe it is the future of drug R&D. Review a case study and learn more about Functional Diagnosis here.